Berkeley Heights, NJNCT07357727Now EnrollingIRB Ready

Primary Myelofibrosis (PMF) Clinical Trial in Berkeley Heights, NJ

Access cutting-edge primary myelofibrosis (pmf) treatment through this clinical trial at a research site in Berkeley Heights. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Berkeley Heights location

Preparing your pre-screening questions…

Expert Care in Berkeley Heights

Access primary myelofibrosis (pmf) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related primary myelofibrosis (pmf) treatment provided free

Apply for This Berkeley Heights Location

Check if you qualify for this primary myelofibrosis (pmf) clinical trial in Berkeley Heights, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Berkeley Heights

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Berkeley Heights site if eligible
  4. 4Begin participation

About This Primary Myelofibrosis (PMF) Study in Berkeley Heights

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Participants have diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocythemia myelofibrosis (post-ET MF) according to the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemias 2022
DIPSS risk category of intermediate-1, intermediate-2 or high-risk
Spleen volume ≥ 450 cm3 by CT or MRI scan (local read sufficient if no central read available)
Have an average TSS of ≥15 within 7 days prior to randomization, using MFSAF v. 4.0 (at least 4 out of 7 TSS assessments required for average calculation)
Participants with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
Blasts \<5% in peripheral blood. Assessment of blasts in peripheral blood is mandatory at screening
Platelet count ≥ 100 x 10\^9/L in the absence of growth factors or transfusions for the previous 4 weeks Key

Exclusion Criteria

Prior splenectomy at any time or splenic irradiation in the previous 6 months
Prior hematopoietic cell transplant or participant anticipated to receive a hematopoietic cell transplant within 24 weeks from the date of randomization
Blasts ≥ 5% in bone marrow if results available at screening or history of accelerated phase (AP) or leukemic transformation
History of a malignancy (other than MF, PPV-MF or PET-MF) in the past 3 years in need of systemic treatment
Received any approved or investigational agent other than hydroxyurea or anagrelide for the treatment of MF within 14 days of first dose of study treatment or within 5 half-lives of the approved or investigational agent, whichever is longer
Prior treatment with any JAK inhibitor or Bromodomain and extraterminal domain (BET) inhibitor Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Berkeley Heights?

Yes, this clinical trial (NCT07357727) has an active research site in Berkeley Heights, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Myelofibrosis (PMF) Treatment Options in Berkeley Heights, NJ

If you're searching for primary myelofibrosis (pmf) treatment options in Berkeley Heights, NJ, this clinical trial (NCT07357727) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Berkeley Heights research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary myelofibrosis (pmf) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary myelofibrosis (pmf) clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Berkeley Heights, NJ

See all myeloproliferative neoplasms clinical trials recruiting in Berkeley Heights — not just this study.

Browse Myeloproliferative Neoplasms Trials in Berkeley Heights →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsFibromyalgia TrialsMyelofibrosis TrialsAll Conditions →

Ready to Join in Berkeley Heights?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Berkeley Heights, NJ